{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:09:38Z","timestamp":1780445378015,"version":"3.54.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China Grant","doi-asserted-by":"crossref","award":["82172642"],"award-info":[{"award-number":["82172642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10637-024-01437-z","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:02:00Z","timestamp":1714726920000},"page":"335-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-8939","authenticated-orcid":false,"given":"Wenjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1038\/s41388-020-1193-8","volume":"39","author":"JP Koch","year":"2020","unstructured":"Koch JP, Aebersold DM, Zimmer Y et al (2020) MET targeting: time for a rematch. Oncogene 39:2845\u20132862","journal-title":"Oncogene"},{"key":"1437_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K et al (2019) MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol 12:63","journal-title":"J Hematol Oncol"},{"key":"1437_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","volume":"26","author":"Y Dong","year":"2022","unstructured":"Dong Y, Xu J, Sun B et al (2022) MET-targeted therapies and clinical outcomes: a systematic literature review. Mol Diagn Ther 26:203\u2013227","journal-title":"Mol Diagn Ther"},{"key":"1437_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han J-Y et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944\u2013957","journal-title":"N Engl J Med"},{"key":"1437_CR5","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","volume":"50","author":"YD Yan","year":"2022","unstructured":"Yan YD, Zhao Y, Zhang C et al (2022) Toxicity spectrum of immunotherapy in advanced lung cancer: a safety a nalysis from clinical trials and a pharmacovigilance system. EClinicalMedicine 50","journal-title":"EClinicalMedicine"},{"key":"1437_CR6","doi-asserted-by":"publisher","first-page":"1266890","DOI":"10.3389\/fphar.2023.1266890","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, Li F, Hou Y et al (2023) Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study. Front Pharmacol 14:1266890","journal-title":"Front Pharmacol"},{"key":"1437_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/CMAR.S386799","volume":"15","author":"M Fraser","year":"2023","unstructured":"Fraser M, Seetharamu N, Diamond M et al (2023) Profile of capmatinib for the treatment of metastatic non-small cell lung cancer (NSCLC): patient selection and perspectives. J Cancer Manag Res 15:1233\u20131243","journal-title":"J Cancer Manag Res"},{"key":"1437_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R et al (2020) Tepotinib in non-small-cell lung cancer with MET Exon 14 skippi ng mutations. N Engl J Med 383:931\u2013943","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01437-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:11:31Z","timestamp":1718017891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01437-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01437-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No ethics approval and written consent were needed for the secondary analysis of public data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare that the study was performed in the absence of the conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}